Tags

Type your tag names separated by a space and hit enter

Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study).
Br J Cancer. 2001 Nov 30; 85(11):1646-54.BJ

Abstract

PURPOSE

(1) To improve survival rates in patients with Ewing's sarcoma (ES) or peripheral neuroectodermal tumours (PNET) using semi-continuous chemotherapy and aiming to perform surgery in all; (2) To identify early prognostic factors to tailor therapy for future studies.

PATIENTS AND METHODS

One hundred and forty-one patients were entered onto the trial between January 1988 and December 1991. Induction therapy consisted of five courses of Cytoxan, 150 mg/m(2) x 7 days, followed by Doxorubicin, 35 mg/m(2) i.v on day 8 given at short intervals. Surgery was recommended whenever possible. The delivery of radiation therapy was based on the quality of resection and the histological response to CT. Maintenance chemotherapy consisted of vincristine + actinomycin and cytoxan + doxorubicin. The total duration of therapy was 10 months.

RESULTS

After a median follow-up of 8.5 years, the projected overall survival at 5 years was 66% and disease-free survival (DFS) was 58%. In patients treated by surgery, only the histological response to CT had an influence on survival: 75% DFS for patients with a good histological response (less than 5% of cells), 48% for intermediate responders and only 20% for poor responders (> or = 30% of cells), P < 0.0001. The initial tumor volume by itself had no influence on DFS in these patients. In contrast, the tumour volume had a strong impact on DFS in patients treated by radiation therapy alone. Age had no impact on outcome.

CONCLUSION

Therapeutic trials for localized Ewing's sarcoma should be based on the histological response to chemotherapy or on the tumour volume according to the modality used for local therapy.

Authors+Show Affiliations

Pédiatrie Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11742482

Citation

Oberlin, O, et al. "Prognostic Factors in Localized Ewing's Tumours and Peripheral Neuroectodermal Tumours: the Third Study of the French Society of Paediatric Oncology (EW88 Study)." British Journal of Cancer, vol. 85, no. 11, 2001, pp. 1646-54.
Oberlin O, Deley MC, Bui BN, et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001;85(11):1646-54.
Oberlin, O., Deley, M. C., Bui, B. N., Gentet, J. C., Philip, T., Terrier, P., Carrie, C., Mechinaud, F., Schmitt, C., Babin-Boillettot, A., & Michon, J. (2001). Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). British Journal of Cancer, 85(11), 1646-54.
Oberlin O, et al. Prognostic Factors in Localized Ewing's Tumours and Peripheral Neuroectodermal Tumours: the Third Study of the French Society of Paediatric Oncology (EW88 Study). Br J Cancer. 2001 Nov 30;85(11):1646-54. PubMed PMID: 11742482.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). AU - Oberlin,O, AU - Deley,M C, AU - Bui,B N, AU - Gentet,J C, AU - Philip,T, AU - Terrier,P, AU - Carrie,C, AU - Mechinaud,F, AU - Schmitt,C, AU - Babin-Boillettot,A, AU - Michon,J, AU - ,, PY - 2001/12/18/pubmed PY - 2002/1/24/medline PY - 2001/12/18/entrez SP - 1646 EP - 54 JF - British journal of cancer JO - Br. J. Cancer VL - 85 IS - 11 N2 - PURPOSE: (1) To improve survival rates in patients with Ewing's sarcoma (ES) or peripheral neuroectodermal tumours (PNET) using semi-continuous chemotherapy and aiming to perform surgery in all; (2) To identify early prognostic factors to tailor therapy for future studies. PATIENTS AND METHODS: One hundred and forty-one patients were entered onto the trial between January 1988 and December 1991. Induction therapy consisted of five courses of Cytoxan, 150 mg/m(2) x 7 days, followed by Doxorubicin, 35 mg/m(2) i.v on day 8 given at short intervals. Surgery was recommended whenever possible. The delivery of radiation therapy was based on the quality of resection and the histological response to CT. Maintenance chemotherapy consisted of vincristine + actinomycin and cytoxan + doxorubicin. The total duration of therapy was 10 months. RESULTS: After a median follow-up of 8.5 years, the projected overall survival at 5 years was 66% and disease-free survival (DFS) was 58%. In patients treated by surgery, only the histological response to CT had an influence on survival: 75% DFS for patients with a good histological response (less than 5% of cells), 48% for intermediate responders and only 20% for poor responders (> or = 30% of cells), P < 0.0001. The initial tumor volume by itself had no influence on DFS in these patients. In contrast, the tumour volume had a strong impact on DFS in patients treated by radiation therapy alone. Age had no impact on outcome. CONCLUSION: Therapeutic trials for localized Ewing's sarcoma should be based on the histological response to chemotherapy or on the tumour volume according to the modality used for local therapy. SN - 0007-0920 UR - https://www.unboundmedicine.com/medline/citation/11742482/Prognostic_factors_in_localized_Ewing's_tumours_and_peripheral_neuroectodermal_tumours:_the_third_study_of_the_French_Society_of_Paediatric_Oncology__EW88_study__ L2 - http://dx.doi.org/10.1054/bjoc.2001.2150 DB - PRIME DP - Unbound Medicine ER -